Xeris Pharmaceuticals, Inc. (XERS)
| Market Cap | 261.53M |
| Revenue (ttm) | 15.09M |
| Net Income (ttm) | -102.37M |
| Shares Out | 46.15M |
| EPS (ttm) | -2.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $5.34 |
| Previous Close | $5.28 |
| Change ($) | 0.06 |
| Change (%) | 1.14% |
| Day's Open | 5.20 |
| Day's Range | 5.19 - 5.44 |
| Day's Volume | 1,035,102 |
| 52-Week Range | 1.49 - 6.59 |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and co...
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and co...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...
Last year, I was neutral about the Xeris Pharmaceuticals story; but a lot of positives have happened this year. There's a marketed product, a steadily rising revenue stream, a platform with po...
Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q3 2020 Results - Earnings Call Transcript
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 35.19% and 111.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead fo...
Shares of Xeris Pharmaceuticals (NASDAQ:XERS) moved higher by 4.6% in pre-market trading after the company reported Q3 results.
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and co...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize read...
Xeris Pharmaceuticals (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...
Xeris has rallied substantially off its recent lows as Gvoke sales numbers have been promising.
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize read...
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.
Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q2 2020 Results - Earnings Call Transcript
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 11.27% and -11.18%, respectively, for the quarter ended June 2020.
Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 3% in pre-market trading after the company reported Q2 results.
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize read...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize read...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and co...
Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...
Xeris Pharmaceuticals' (XERS) CEO Paul Edick on Q1 2020 Results - Earnings Call Transcript
Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...
As of late, it has definitely been a great time to be an investor in Xeris Pharmaceuticals.
Xeris Pharmaceuticals, Inc.'s (XERS) CEO Paul Edick on Q4 2019 Results - Earnings Call Transcript
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 0.81% and 144.30%, respectively, for the quarter ended December 2019.
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CHICAGO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commerciali...
CHICAGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commerciali...
Xeris Pharmaceuticals Inc (NASDAQ: XERS) shares are advancing on above-average volume Tuesday following a positive data readout from the company.
Xeris Pharmaceuticals, Inc. shares pushed higher on Tuesday after the firm announced positive topline results from its mid-stage study in adults with Type 1 diabetes mellitus (T1D).
Xeris Pharmaceuticals Inc. shares rallied in the extended session Monday after the drug maker said its diabetes treatment showed positive results in a mid-stage clinical study.
CHICAGO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commerciali...
CHICAGO, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commerciali...
MAA submitted to EMA of liquid stable glucagon for severe hypoglycemia GVOKE ™ PFS launch underway GVOKE HypoPen ™ expected to launch July 2020 CHI program shifts to Expanded Acce...
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 3.17% and 61.50%, respectively, for the quarter ended September 2019.
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercial...
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) shares were halted briefly on Tuesday after the firm announced that it has received regulatory approval from the U.S.
Xeris Pharma’s Gvoke is a stable and ready to use glucagon self-injector therapy.
About XERS
Xeris Pharmaceuticals, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a... [Read more...]
| Industry Biotechnology | IPO Date Jun 21, 2018 |
| CEO paul Edick | Employees 172 |
| Stock Exchange NASDAQ | Ticker Symbol XERS |
Financial Performance
In 2019, XERS's revenue was $2.72 million, an increase of 12.34% compared to the previous year's $2.42 million. Losses were -$125.58 million, 109.0% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is 11.00, which is an increase of 105.99% from the latest price.